| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Abstracts - Monday June 23rd 2003 1630 - 1800 |
Department of Anesthesia, Hospital Clinicas Caracas & Policlinica Mendez Gimon. Caracas - Venezuela
INTRODUCTION
Beside regression plotting of transformed data, potency can be obtained from a single data point if the slope of this relationship is assumed, averaging individual estimates determined by using the modifications of the Hill equation (1, 2). The interaction between rocuronium (ROC) and vecuronium (VEC) already studied by others (3) was revisited by using such an alternate method.
METHODS
After institutional informed and signed consent 135 elective patients (44±4 years, 68±3 Kg) anesthetized with intravenous agents and ventilated with nitrous oxide-oxygen, were randomly allocated to nine groups (n=15) according to the amount and type of muscle relaxant administered. Single drug dose-response relationship were concluded first using ROC 50, 100 and 200 µgKg-1 or VEC 10, 20 and 30 µgKg-1 and ED50's determined by the above mentioned method, using the maximal effect obtained by electromyography and train-of-four stimulation. Subsequently ED50 for the ROC+VEC combination was calculated using 0.2, 0.3 and 0.4 fractions of each ED50 by the same alternate method. An algebraic analysis was used to identify the type of interaction: (dr/(ED50)r+dv(ED50)v) (3).
RESULTS
Algebraic analysis shows a value less than 1 indicating additivism (Table 1
). For comparison results from a previous work using log/probit transformation for calculations are also included (3).
|
Highly similar figures obtained by either one results suggest that this alternate method is a reliable and useful tool for the calculation of a dose-response relationship and seems to be used for the first time for VEC and it's interaction with ROC.
REFERENCES
1 : Anesth Analg (2000) 90: 1191.
2 Anesthesiology (1994) 81: 159.
3 ,: Br J Anaesth (1995) 75: 37.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |